Market closed

Edgewise Therapeutics/$EWTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Edgewise Therapeutics

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Ticker

$EWTX
Trading on

Industry

Pharmaceuticals

Employees

110

EWTX Metrics

BasicAdvanced
$1.6B
-
-$1.45
0.23
-
$1.6B
0.23
$35.66
$10.60
2.4M
19.928
19.705
0.815
1.032
-24.01%
-34.40%
3.19
3.19
-12.948
-7.88%
8.27%

What the Analysts think about EWTX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Edgewise Therapeutics stock.

EWTX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

EWTX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EWTX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Edgewise Therapeutics stock?

Edgewise Therapeutics (EWTX) has a market cap of $1.6B as of May 01, 2025.

What is the P/E ratio for Edgewise Therapeutics stock?

The price to earnings (P/E) ratio for Edgewise Therapeutics (EWTX) stock is 0 as of May 01, 2025.

Does Edgewise Therapeutics stock pay dividends?

No, Edgewise Therapeutics (EWTX) stock does not pay dividends to its shareholders as of May 01, 2025.

When is the next Edgewise Therapeutics dividend payment date?

Edgewise Therapeutics (EWTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Edgewise Therapeutics?

Edgewise Therapeutics (EWTX) has a beta rating of 0.23. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.